With a US filing for its Stelara (ustekinumab) biosimilar in hand, Biocon Biologics has now secured a February 2025 launch date for its proposed Bmab 1200 version, assuming US Food and Drug Administration approval.
A settlement and license agreement signed with Johnson & Johnson and its Janssen Biotech unit has dismissed a pending Inter Partes Review for Stelara’s US patent 10,961,307 – which is due to expire on 24 September 2039 – before the Patent Trial and Appeal Board of the US Patent and Trademarks Office